Utah Medical Products, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
January 31, 2023 at 09:00 am EST
Share
Utah Medical Products, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was USD 13.58 million compared to USD 12.91 million a year ago. Net income was USD 4.56 million compared to USD 4.13 million a year ago. Diluted earnings per share from continuing operations was USD 1.253 compared to USD 1.127 a year ago.
For the full year, sales was USD 52.28 million compared to USD 49.05 million a year ago. Net income was USD 16.47 million compared to USD 14.79 million a year ago. Diluted earnings per share from continuing operations was USD 4.522 compared to USD 4.041 a year ago.
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.
UTAH MEDICAL PRODUCTS, INC. 
